Daytime sleepiness in elderly Parkinson's disease patients and treatment with the psychostimulant modafinil: A preliminary study

Neuropsychiatric Disease and Treatment

Volumn 6, Issue 1, 2010, Pages 93-97

  Lökk, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Daytime sleepiness; Epworth sleepiness scale; Parkinson's disease; Psychostimulant

Indexed keywords

LEVODOPA; MODAFINIL;

AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EPWORTH SLEEPINESS SCALE; FEMALE; HEART RATE; HUMAN; INCREASED APPETITE; MALE; MORNING DOSAGE; PARKINSON DISEASE; QUALITY OF LIFE; SOCIAL LIFE; TREATMENT RESPONSE; WAKEFULNESS;

EID: 77950793286     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s9138     Document Type: Article

References (31)

1. Larsen JP. Sleep disorders in Parkinson's disease. Adv Neurol. 2003;91:329-334.
2. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA. 2002;287:455-463.
3. Gjerstad MD, Aarsland D, Larsen JP. Development of daytime somnolence over time in Parkinson's disease. Neurology. 2002;58:1544-1546.
4. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev. 2005;9:185-200.
5. George PT. Sleepiness, troika of consciousness cycle, and the Epworth sleepiness scale. Sleep Breath. 2001;5:181-191.
6. Black J, Duntley SP, Bogan RK, O'Malley MB. Recent advantages in the management of excessive daytime sleepiness. CNS Spectr. 2007;12:1-14.
7. Meindorfner C, Körner Y, Möller JC, Stiasny-Kolster K, Oertel WH, Krüger HP. Driving in Parkinson's disease: mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord. 2005;20:832-842.
8. Rye DB. Excessive daytime sleepiness and unintended sleep in Parkinson's disease. Curr Neurol Neurosci Rep. 2006;6:169-176.
9. Cole C, Richards K. Sleep disruption in older adults. Harmful and by no means inevitable, it should be assessed for and treated. Am J Nurs. 2007;107:40-49.
10. Nagels G, D'hooghe MB, Vleugels L, Kos D, Despontin M, De Deyn PP. P300 and treatment effect of modafinil on fatigue in multiple sclerosis. J Clin Neurosci. 2007;14:33-40.
11. Prommer E. Modafinil: is it ready for prime time? J Opioid Manag. 2006;2:130-136.
12. Nieves AV, Lang AE. Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol. 2002;25:111-114.
13. Högl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, cross-over, placebo-controlled polygraphic trial. Sleep. 2002;25: 905-909.
14. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord. 2003;18:287-293.
15. Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76:1636-1639.
16. van Vliet SA, Blezer EL, Jongsman MJ, Vanwersch RA, Olivier B, Philippens IH. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy. Brain Res. 2008;11189:219-228.
17. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42:123-137.
18. FASS Pharmaceutical Specialities in Sweden. Available from: http://www.fass.se. Accessed February 10, 2010.
19. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14:540-545.
20. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinon's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
21. Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. REM sleep behaviour disorder in Parkinson's disease is associated with specific motor features. J Neurol Neurosurg Psychiatry. 2008;79:1117-1121.
22. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML, editors. Third Symposium on Parkinson's Disease E & S. Edinburgh, UK: Livingstone; 1969.
23. Schneider LS, Olin JT. Clinical Global Impression of Change. Clinical global impressions in Alzheimers clinical trials. Int Psychogeriatr. 1996;8:277-290.
24. Mignot E, Nishino S, Guilleminault C, Dement WS. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994;17: 436-437.
25. Happe S, Baier BC, Helmschmied K, Meller J, Tatsch K, Paulus W. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. J Neurol. 2007;254: 1037-1043.
26. Kayukawa Y, Kogawa S, Tadano F, et al. Sleep problems in the aged in relation to senility. Psychiatry Clin Neurosci. 1998;52:190-192.
27. Jahan I, Hauser RA, Sullivan KL, Miller A, Zesiewisc TA. Sleep disorders in Parkinson's disease. Neuropsychiatr Dis Treat. 2009;5: 535-540.
28. Tamaki M, Shirota A, Tanaka H, Hayashi M, Hori T. Effects of a daytime nap in the aged. Psychiatry Clin Neurosci. 1999;53: 273-275.
29. Choo KL, Guilleminault C. Narcolepsy and idiopathic hypersomnolence. Clin Chest Med. 1998;19:169-181.
30. Haw C, Stubbs J. Off-label use of anti-psychotics: are we mad? Expert Opin Drug Saf. 2007;6:533-545.
31. Frisoni GB, Canu E, Geroldi C, Brignoli B, Anglani L, Galuzzi S, et al. Prescription patterns and efficacy of drugs for patients with dementia: physicians' perspective in Italy. Aging Clin Exp Res. 2007;19:349-355.